Leonardo Gómez Rosso
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Leonardo Gómez Rosso.
Atherosclerosis | 2014
Leonardo Gómez Rosso; Marie Lhomme; Tomás Meroño; Patricia Sorroche; Luis J. Catoggio; Enrique R. Soriano; Carla Saucedo; Verónica Malah; Carolane Dauteuille; Laura Boero; Philippe Lesnik; Paul Robillard; M. John Chapman; Fernando Brites; Anatol Kontush
OBJECTIVE High-density lipoprotein (HDL) particles exert potent antiatherogenic activities, including antioxidative actions, which are relevant to attenuation of atherosclerosis progression. Such activities are enriched in small, dense HDL and can be compromised under conditions of chronic inflammation like rheumatoid arthritis (RA). However, structure-function relationships of HDL largely remain indeterminate. METHODS The relationships between HDL structure and function were evaluated in normolipidemic patients with active RA (DAS28 > 3.2; n = 12) and in normolipidemic age-matched controls (n = 10). Small, dense HDL3b and 3c particles were isolated from plasma or serum by density gradient ultracentrifugation and their physicochemical characteristics, lipidome (by LC/MS/MS) and antioxidative function (as protection of normolipidemic LDL from free radical-induced oxidation) were evaluated. RESULTS As expected, active RA patients featured significantly elevated plasma levels of high-sensitivity C-reactive protein (hsCRP; p < 0.001) and serum amyloid A (SAA; p < 0.01) relative to controls. Antioxidative activity and weight % chemical composition of small, dense HDL did not differ between RA patients and controls (p > 0.05), whereas HDL phosphosphingolipidome was significantly altered in RA. Subgroup analyses revealed that RA patients featuring high levels of inflammation (hsCRP>10 mg/l) possessed small, dense HDL with reduced antioxidative activities (p < 0.01). Furthermore, antioxidative activity of HDL was inversely correlated with plasma hsCRP (p < 0.01). CONCLUSIONS These data revealed that (i) despite normolipidemic state, the lipidome of small, dense HDL was altered in RA and (ii) high levels of inflammation can be responsible for the functional deficiency of small, dense HDL in RA.
European Journal of Endocrinology | 2011
Gabriela Brenta; Jorge Thierer; Marcela Sutton; Adriana Acosta; Nora Vainstein; Fernando Brites; Laura Boero; Leonardo Gómez Rosso; Stefan D. Anker
BACKGROUND Low plasma triiodothyronine (T(3)) levels are considered a prognostic predictor of death in heart failure (HF) patients. AIM To study an association between plasma T(3) levels and several cardiac, neurohormonal, and metabolic markers of HF. METHODS A total of 133 ambulatory HF patients (114 males; mean age 63.2 years) with left ventricular ejection fraction <40% were enrolled. TSH, total tetraiodothyronine (T(4)) and T(3), N-terminal pro-brain natriuretic peptide (NT-proBNP), and other cardiac and metabolic parameters were measured. The lowest tertile of T(3) (group 1) was compared against the two upper ones (group 2). RESULTS In simple logistic regression, the lowest T(3) tertile was associated with more advanced HF disease status: older (age: odds ratio (OR)=1.05; confidence interval (CI) 95% 1.01-1.09, P=0.004), lower functional capacity (walking test: OR=0.996; CI 95% 0.993-0.999, P=0.008), higher NT-proBNP (OR=1.64; CI 95% 1.19-2.27, P=0.003) and adiponectin levels (OR=1.07; CI 95% 1.02-1.11, P=0.004), lower DHEAS log-transformed (OR=0.50; CI 95% 0.31-0.80, P=0.004), and the presence of lower phase angle values as measured by body bioelectrical impedance analysis (OR=3.18; CI 95% 1.50-6.71, P=0.04) and worse renal function (OR=0.96; CI 95% 0.94-0.98, P=0.003). T(3) levels in the lowest tertile were independently associated with low phase angle values (OR=2.95, CI 95% 1.16-7.50, P=0.02) and the log transformation of DHEAS (OR=0.56; CI 95% 0.32-0.97, P=0.04). CONCLUSION We have demonstrated an association between plasma T(3) levels in the lower range and other deranged hormonal and metabolic parameters in HF patients.
Cardiovascular and Hematological Agents in Medicinal Chemistry | 2011
Valeria Hirschler; Tomás Meroño; Gustavo Maccallini; Leonardo Gómez Rosso; Claudio Aranda; Fernando Brites
BACKGROUND Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) has been proposed as a biomarker of risk of cardiovascular disease (CVD). OBJECTIVE To determine the association between Lp-PLA(2) activity and BMI, insulin-resistance, components of the metabolic syndrome (MS), and lifestyle behaviors in healthy adolescent boys. METHODS Data were collected cross-sectionally from 164 adolescents from an amateur rugby club. BMI, blood pressure (BP), Tanner stages, glucose, insulin, lipids, and Lp-PLA(2) activity were measured. Questionnaires for lifestyle behaviors were completed. RESULTS Approximately 26% of the adolescents were obese and 23% overweight. There was a univariate association between Lp-PLA(2) and BMI (r=0.16;p=0.042), triglycerides (r=0.26;p=0.001), LDL-C (r=0.46;p<0.001), apo B (r=0.55;p<0.001), whereas waist circumference , BP, glucose, HOMA-IR, and HDL-C were not correlated. None of the lifestyle behaviors were significantly correlated with Lp-PLA(2). In order to analyze Lp-PLA(2) association with known CVD risk conditions, adolescents were categorized according to overweight/obesity and to the presence of metabolic syndrome. Conversely, as it was for LDL-C and apo B concentration, Lp-PLA(2) activity was not higher in adolescents with obesity. Multiple regression analysis showed that apo B was significantly associated with Lp-PLA(2) adjusted for age, BMI, triglycerides and LDL-C (R2=0.32). CONCLUSION Lp-PLA(2) activity was only associated with apo B adjusted for several confounding variables, suggesting that its clinical utility to identify individuals at risk for CVD does not surpass LDL-C and apo B in healthy adolescents. As plaque morphology may change with age, associations of Lp-PLA(2) with CVD may likewise vary with age.
Acta Bioquimica Clinica Latinoamericana | 2008
Natalia Elissondo; Leonardo Gómez Rosso; Patricia Maidana; Fernando Brites
Endocrine Practice | 2015
Laura Boero; Marcos Manavela; Eliana Botta; María Susana Mallea-Gil; Débora Katz; Tomás Meroño; Walter Tetzlaff; Maximiliano Martin; Leonardo Gómez Rosso; Karina Danilowicz; Fernando Brites
Acta Bioquimica Clinica Latinoamericana | 2007
Gabriela Berg; Fernando Brites; María Luz Muzzio; Valeria Zago; Graciela López; María Belén Benítez; Leonardo Gómez Rosso; Verónica Miksztowicz; Leonardo Cacciagiú; Ana Inés González; Laura Aisemberg; Laura Schreier; Regina Wikinski
Atherosclerosis | 2015
Leonardo Gómez Rosso; Marie Lhomme; Tomás Meroño; Patricia Sorroche; Luis J. Catoggio; Enrique R. Soriano; Carla Saucedo; Verónica Malah; Carolane Dauteuille; Laura Boero; Philippe Lesnik; Paul Robillard; M. John Chapman; Fernando Brites; Anatol Kontush
Archive | 2013
Martín Menafra; Tomás Meroño; Maria Dolores Matoso; Laura Boero; Leonardo Gómez Rosso; María Soledad Saez; Patricia Sorroche; Fernando Brites
Argentine Journal of Cardiology | 2012
Gustavo Giunta; Eduardo Guevara; Leandro Marziali; Leonardo Gómez Rosso; Tomás Meroño; Roberto Favaloro; Fernando Brites; Luis Cuniberti
Archive | 2008
Natalia Elissondo; Leonardo Gómez Rosso; Patricia Maidana; Fernando Brites